Pharvaris N.V. (PHVS)
| Market Cap | 2.41B +54.1% |
| Revenue (ttm) | n/a |
| Net Income | -195.27M |
| EPS | -2.99 |
| Shares Out | 70.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 179,837 |
| Open | 34.01 |
| Previous Close | 33.99 |
| Day's Range | 33.82 - 34.73 |
| 52-Week Range | 22.41 - 43.25 |
| Beta | -2.52 |
| Analysts | Strong Buy |
| Price Target | 57.68 (+68.31%) |
| Est. Earnings | Nov 24, 2026 |
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a... [Read more]
Analyst Summary
According to 14 analysts, the average rating for PHVS stock is "Strong Buy." The 12-month stock price target is $57.68, which is an increase of 68.31% from the latest price.
News
Pharvaris Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Deucrictibant’s on-demand PDUFA is set for April 23, 2027, while prophylaxis NDA preparation depends on H1 2027 safety data. CREATE results are expected in Q1 2027, and commercial preparations are nearing completion.
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November...
Pharvaris upgraded to Buy at BofA after ‘valuation reset’
As previously reported, BofA upgraded Pharvaris (PHVS) to Buy from Neutral with an unchanged price target of $44. Shares have pulled back since the positive Phase 3 prophylactic data in…
Pharvaris upgraded to Buy from Neutral at BofA
BofA analyst Tazeen Ahmad upgraded Pharvaris (PHVS) to Buy from Neutral with an unchanged price target of $44.
Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial
Pharvaris (PHVS) announced that results of RAPIDe-3, a phase 3 crossover study evaluating oral deucrictibant immediate-release capsule for the on-demand treatment of hereditary angioedema – HAE – atta...
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of t...
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight o...
Pharvaris Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Deucrictibant, an oral therapy for hereditary angioedema, demonstrated strong efficacy and safety in phase III trials, with regulatory reviews progressing in the US and Europe. Commercial launch preparations are on track for 2024, and the pipeline is expanding to address broader bradykinin-mediated disorders.
Pharvaris Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Deucrictibant achieved high efficacy in severe HAE patients, with a strong safety profile and unique benefits for normal C1 patients. Launch preparations for both on-demand and prophylactic formulations are progressing, with regulatory milestones and global expansion under evaluation.
Pharvaris Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Deucrictibant demonstrated strong phase III efficacy for both prophylactic and on-demand HAE treatment, including in diverse and type 3 patient populations. Safety profile is favorable and comparable to existing therapies. Launch preparations are advanced, with a strategic focus on maximizing market share and expanding indications.
Pharvaris price target raised to $44 from $40 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Pharvaris (PHVS) to $44 from $40 and keeps a Buy rating on the shares after deucrictibant extended-release tablet for the…
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded BioCryst (BCRX) to Sector Perform from Outperform with a price target of $11, down from $13. BioCryst faces a more challenging near-term outlook as stronger-than-expected Pharva...
Pharvaris Transcript: Wells Fargo 21st Annual Healthcare Conference
Deucrictibant demonstrated high efficacy in phase III HAE prophylaxis, matching injectables and offering oral convenience. Safety profile aligns with existing therapies, and broad patient coverage—including normal C1—positions it for strong commercial uptake. Regulatory filings are planned for next year.
Pharvaris price target raised to $50 from $42 at Wedbush
Wedbush raised the firm’s price target on Pharvaris (PHVS) to $50 from $42 and keeps an Outperform rating on the shares. The firm notes the CHAPTER-3 readout landed in-line with…
Pharvaris price target raised to $65 from $50 at Leerink
Leerink raised the firm’s price target on Pharvaris (PHVS) to $65 from $50 and keeps an Outperform rating on the shares. The company reported “stellar” Phase 3 data for deucrictibant…
Pharvaris price target raised to $62 from $52 at RBC Capital
RBC Capital analyst Nevin Varghese raised the firm’s price target on Pharvaris (PHVS) to $62 from $52 and keeps an Outperform rating on the shares. Pharvaris’ CHAPTER-3 results look like…
Pharvaris price target raised to $62 from $46 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Pharvaris (PHVS) to $62 from $46 and keeps an Overweight rating on the shares after the company’s CHAPTER-3 prophylaxis study met the…
Pharvaris price target raised to $65 from $55 at Wells Fargo
Wells Fargo raised the firm’s price target on Pharvaris (PHVS) to $65 from $55 and keeps an Overweight rating on the shares. The firm notes Deucrictibant showed injectable like efficacy,…
Pharvaris price target raised to $65 from $52 at Jones
Jones analyst Debanjana Chatterjee raised the firm’s price target on Pharvaris (PHVS) to $65 from $52 and keeps a Buy rating on the shares. The firm cites the positive Phase…
Pharvaris price target raised to $79 from $75 at Citizens
Citizens raised the firm’s price target on Pharvaris (PHVS) to $79 from $75 and keeps an Outperform rating on the shares. The CHAPTER-3 results are a clear win, with once-daily…
Pharvaris price target raised to $75 from $50 at Oppenheimer
Oppenheimer raised the firm’s price target on Pharvaris (PHVS) to $75 from $50 and keeps an Outperform rating on the shares after the company announced the primary endpoint and all…
Pharvaris Transcript: Study result
The phase III CHAPTER-3 study showed deucrictibant XR achieved an 83% reduction in HAE attack rates versus placebo, with nearly half of treated patients remaining attack-free over 24 weeks. The drug was well-tolerated, improved quality of life, and offers injectable-like efficacy in an oral formulation.
Pharvaris Press release: Study result
Pharvaris issued a press release on September 8, 2026, disclosing material business information to investors.
Pharvaris Slides: Study result
Pharvaris has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.